These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 496138)

  • 41. Hepatic toxicity of antituberculous drugs in children.
    Allué X; Sanjurjo P; Fidalgo I; Bilbao F
    Helv Paediatr Acta; 1976 Dec; 31(4-5):381-7. PubMed ID: 1017983
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Frequency, diagnosis, and course of hepatotoxic side effects of Rifampicin (author's transl)].
    Deck KA; Gehrhardt A; Klein HO; Ludes H
    Med Klin; 1976 Oct; 71(43):1836-41. PubMed ID: 995024
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The hepatotoxicity of rifampicin and its modification through "essential" choline phospholipids].
    Kuntz HD; Rausch V; Bammel E
    Med Welt; 1978 Mar; 29(11):452-4. PubMed ID: 651600
    [No Abstract]   [Full Text] [Related]  

  • 44. [Experimental study of liver damage due to rifampicin and rifampicin-isoniazid combination].
    Rossolini A; Cellesi C; Debolini A
    Farmaco Prat; 1973 Jun; 28(6):345-55. PubMed ID: 4714054
    [No Abstract]   [Full Text] [Related]  

  • 45. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter?
    Singh J; Garg PK; Thakur VS; Tandon RK
    Indian J Physiol Pharmacol; 1995 Jan; 39(1):43-6. PubMed ID: 7705868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Halothane and antituberculous drugs--a hepatotoxic combination? (author's transl)].
    Schmidt-Wilcke HA; Wolfert W; Grundmann E
    Z Gastroenterol; 1977 Aug; 15(8):504-11. PubMed ID: 906600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Liver toxicity of combined rifampicin-isoniazid-ethambutol medication (author's transl)].
    Austerhoff A; Kindler U; Knop P; Knieriem HJ
    Dtsch Med Wochenschr; 1974 May; 99(22):1182 p. PubMed ID: 4835559
    [No Abstract]   [Full Text] [Related]  

  • 48. Isoniazid-rifampin fulminant hepatitis. A possible consequence of the enhancement of isoniazid hepatotoxicity by enzyme induction.
    Pessayre D; Bentata M; Degott C; Nouel O; Miguet JP; Rueff B; Benhamou JP
    Gastroenterology; 1977 Feb; 72(2):284-9. PubMed ID: 830577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Icterus caused by rifampicin and isoniazide].
    Haber I; Hubens H; Buyssens N
    Tijdschr Gastroenterol; 1974; 17(3):165-76. PubMed ID: 4454055
    [No Abstract]   [Full Text] [Related]  

  • 50. [Clinic-epidemiological significance of drug hepatotoxicity in liver disease consultation].
    Jmelnitzky AC; Guidi M; Bologna A; Viola M; Soccini C; Barbero R; Belloni P; Apraiz M
    Acta Gastroenterol Latinoam; 2000; 30(2):77-84. PubMed ID: 10925723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Animal experimental studies on the problem of liver damage by antitubercular agents (rifampicin and isoniazide) by means of the galactosamine model].
    Leinweber B; Mahrt R
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():300-3. PubMed ID: 1029192
    [No Abstract]   [Full Text] [Related]  

  • 52. Hepatotoxicity of isoniazid and rifampin in children.
    Rugmini PS; Mehta S
    Indian Pediatr; 1984 Feb; 21(2):119-26. PubMed ID: 6469294
    [No Abstract]   [Full Text] [Related]  

  • 53. [Report on 13 cases (including 3 deaths) of liver damage induced by rifampicin (author's transl)].
    Tong YY
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1980 Mar; 3(1):35-8. PubMed ID: 7428575
    [No Abstract]   [Full Text] [Related]  

  • 54. [Nature of the hepatotoxic action of isoniazid (review of the literature)].
    Skakun NP; Shman'ko VV
    Vrach Delo; 1984 Jan; (1):49-52. PubMed ID: 6367216
    [No Abstract]   [Full Text] [Related]  

  • 55. Hepatic dysfunction in tuberculous patients treated with rifampicin and isoniazid.
    Burke M; Logan J
    Ir Med J; 1979 Oct; 72(10):430-4. PubMed ID: 500344
    [No Abstract]   [Full Text] [Related]  

  • 56. Hepatotoxicity of rifampicin and isoniazid in children.
    Casteels-Van Daele M; Igodt-Ameye L; Corbeel L; Eeckels R
    J Pediatr; 1975 May; 86(5):739-41. PubMed ID: 1079531
    [No Abstract]   [Full Text] [Related]  

  • 57. [Anti-tuberculosis chemotherapy and management of adverse reactions].
    Kuwabara K
    Nihon Rinsho; 2011 Aug; 69(8):1389-93. PubMed ID: 21838035
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Hepatotoxicity of rifampicin-rifamycin SV in the treatment of tuberculous meningitis (author's transl)].
    Ziebart-Schroth A
    Wien Klin Wochenschr; 1973 Oct; 85(42):692-5. PubMed ID: 4128922
    [No Abstract]   [Full Text] [Related]  

  • 59. [Severe hepatotoxicity of tuberculostatic agents. Increase in the incidence].
    Moitinho E; Salmerón JM; Mas A; Bruguera M; Rodés J
    Gastroenterol Hepatol; 1996 Nov; 19(9):448-51. PubMed ID: 8998667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.
    Prince MI; Burt AD; Jones DE
    Gut; 2002 Mar; 50(3):436-9. PubMed ID: 11839728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.